ImmunoGen’s Investigative Therapy for Ovarian Cancer Shows Potential in Clinical Studies

ImmunoGen’s Investigative Therapy for Ovarian Cancer Shows Potential in Clinical Studies
ImmunoGen will show promising safety and efficacy data of its investigative treatment mirvetuximab soravtansine for the treatment of FRα-positive epithelial ovarian cancer (EOC). The positive top-line data will be presented in three poster sessions at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting June 2-6 in Chicago. Mirvetuximab soravtansine (IMGN853) belongs to a class of medications known as

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *